ASX-listed biotechs continue to make a mark globally, but are often put in the ‘too hard basket’ by investors. This half day virtual event aims to change that. ausbiz, in partnership with the ASX, invites you to attend "Biotech Unlocked: Showcasing Australia's Next Investment Horizon" on Thursday, November 4th from 9.00am.

Experts will explain why biotechs are worthy investments; there will also be a 'valuation masterclass' to help you better understand how and why biotechs are valued as they are, and how to ascribe value in the future.

This event will also showcase some of the most exciting ASX-listed biotech companies, featuring in-depth conversations with the CEOs to uncover how they will capitalise on milestones to unlock future returns.
Thu, Nov 4, 2021 · 9:00 AM Sydney (GMT 11:00)
  • 9.00:
  • 9.10: The Investment Thesis.
  • 9.35: Biotech showcase ONE (plus Q&A)
  • 9.55: Lightning round one - meet the CEO's of two biotech small caps
  • 10.00: Biotech showcase TWO (plus Q&A)
  • 10.20: Lightning round two - meet the CEO's of two biotech small caps
  • 10.25: Biotech showcase THREE (plus Q&A)
  • 10.45: Lightning round three - meet the CEO's of two biotech small caps
  • 10.50: Biotech showcase FOUR (plus Q&A)
  • 11.10 Biotech showcase FIVE (plus Q&A)
  • 11.30: Valuation Masterclass. Whiteboard session - a fund manager talks through a biotech they hold and how they performed the valuation.
  • 12.00: Close
Elyse Shapiro
Healthcare Analyst, Cannacord Genuity
Hashan De Silva
Head of Healthcare Research, Karst Peak Capital
Matt McNamara
Chief Investment Officer, Horizon 3 Biotech
Chris Kallos
Director and Life Science Analyst, MST Access
Dr. Christian Behrenbruch
CEO & Managing Director, Telix
Dr. Megan Baldwin
CEO & Managing Director, Opthea
Marc Voigt
CEO, Immutep
Leslie Chong
CEO & Managing Director, Imugene
Ralph Highnam
CEO & Managing Director, Volpara